- Home
- FLUX vs BRNS Comparison
FLUX vs BRNS Comparison
Compare FLUX & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FLUX | BRNS |
|---|---|---|
| Founded | N/A | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.3M | 24.1M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | FLUX | BRNS |
|---|---|---|
| Price | $1.05 | $0.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | ★ 132.2K | 20.8K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,317,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $23.01 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 126.25 | N/A |
| 52 Week Low | $0.91 | $0.51 |
| 52 Week High | $7.55 | $2.91 |
Technical Indicators
Market Signals| Indicator | FLUX | BRNS |
|---|---|---|
| Relative Strength Index (RSI) | 48.18 | 54.23 |
| Support Level | $1.04 | $0.65 |
| Resistance Level | $1.20 | $0.75 |
| Average True Range (ATR) | 0.07 | 0.05 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 72.39 | 48.96 |
Price Performance
Historical ComparisonAbout FLUX Flux Power Holdings Inc.
Flux Power Holdings Inc design, develop, manufacture, and sell a portfolio of lithium-ion energy storage solutions for electrification of a range of industrial commercial sectors which include material handling, airport ground support equipment (GSE), and other commercial and industrial applications. It offers a high-power battery cell management system(BMS). The company's BMS provides three functions to its battery systems which include Cell Balancing, Monitoring, and Error Reporting.
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.